2012
DOI: 10.1253/circj.cj-11-0730
|View full text |Cite
|
Sign up to set email alerts
|

Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
52
1

Year Published

2012
2012
2018
2018

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 76 publications
(55 citation statements)
references
References 34 publications
2
52
1
Order By: Relevance
“…9 Kovarnik et al also reported the same results using dual lipid-lowering therapy with statin plus ezetimibe. 23 In the present study, the FF plaque component decreased under statin therapy in both DM and non-DM patients, which illustrated the potential effects of statin against coronary events even in DM patients. The FF component under statin therapy, however, was significantly greater in DM pa- Plaque progression occurs primarily because of an increase in the FI component.…”
Section: Discussionsupporting
confidence: 72%
“…9 Kovarnik et al also reported the same results using dual lipid-lowering therapy with statin plus ezetimibe. 23 In the present study, the FF plaque component decreased under statin therapy in both DM and non-DM patients, which illustrated the potential effects of statin against coronary events even in DM patients. The FF component under statin therapy, however, was significantly greater in DM pa- Plaque progression occurs primarily because of an increase in the FI component.…”
Section: Discussionsupporting
confidence: 72%
“…24 On closer Varying Statin Doses on VH-IVUS Composition examination of the individual VH-IVUS components in our study (Figure 3), the fibrous component was significantly reduced by statin treatment in either group but showed no statistically significant difference between the 2 groups. The changes in fibro-fatty component were too elusive to allow for any conclusion to be drawn from this small sample.…”
Section: Potential Inaccuracy Of Vh-ivus As Compared To Ib-ivusmentioning
confidence: 54%
“…23 In another very recently published report (the Heaven Study by Kovarnik et al), a 12-month dual lipid-lowering therapy (atorvastatin 80 mg and ezetimibe 10 mg) was compared to atorvastatin 10 mg alone. 24 Plaque regression was achieved in the dual therapy group only, yet in both groups treated with atorvastatin, a continuous shift (reduction) of fibrous and fibrofatty component towards (increase) dense calcium and necrotic core was observed. Comparing this recent report with our present study, which also used atorvastatin, both studies showed almost identical trends of plaque composition changes (a closely matched observation of continuous shift in plaque compositions from fibrous and fibro-fatty tissue to dense calcium and necrotic core).…”
Section: Possible Statin-specific Effects On Plaque Compositionsmentioning
confidence: 85%
“…This change in the fibrofatty volume had a significant correlation with changes in the low-density lipoprotein-cholesterol (LDL-C) level (r=0.703, P<0.0001) and in the high-sensitivity C-reactive protein level (r=0.357, P=0.006). 26, 27 Of note, the necrotic core did not change significantly. The same data were found with the use of pitavastatin.…”
Section: Assessment Of Drug Effect On Atherosclerosis By Vh-ivusmentioning
confidence: 93%